{"id":4912,"date":"2026-01-07T09:18:30","date_gmt":"2026-01-07T09:18:30","guid":{"rendered":"https:\/\/profitalarm.com\/index.php\/2026\/01\/07\/top-3-small-cap-medical-device-stocks-updated-january-2026\/"},"modified":"2026-01-07T09:18:30","modified_gmt":"2026-01-07T09:18:30","slug":"top-3-small-cap-medical-device-stocks-updated-january-2026","status":"publish","type":"post","link":"https:\/\/profitalarm.com\/index.php\/2026\/01\/07\/top-3-small-cap-medical-device-stocks-updated-january-2026\/","title":{"rendered":"Top 3 Small-cap Medical Device Stocks (Updated January 2026)"},"content":{"rendered":"<\/p>\n

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone,<\/strong> 30 new devices were approved by the US Food and Drug Administration (FDA).<\/strong><\/p>\n

Wearable medical devices and the use of artificial intelligence in medical technology are two key trends in this sector.<\/p>\n

Investors who want exposure to this wave of growth may want to consider NASDAQ small-cap medical device stocks. Below is a list of the top NASDAQ medical device companies based on year-on-year gains.<\/p>\n

All data was compiled on December 31, 2025, using TradingView\u2019s stock screener, and the medical device makers listed below had market caps between US$50 million and US$500 million at that time.<\/p>\n<\/p>\n

\n
<\/div>\n<\/div>\n
\n

1. MDxHealth (NASDAQ:MDXH)<\/h3>\n

Year-on-year gain:<\/strong> 50.86 percent
Market cap:<\/strong> US$173.24 million
Share price:<\/strong> US$3.50<\/p>\n

MDxHealth is a commercial-stage precision diagnostics company specializing in molecular tests for urologic cancers, particularly prostate cancer, using genomic, epigenetic and exosomal technologies. Its US headquarters and operations are located in Irvine, California.<\/p>\n

The company offers non-invasive and tissue-based diagnostic assays that run on standard PCR platforms. <\/p>\n

<\/span>In September, MDxHealth acquired Exosome Diagnostics from Bio-Techne (NASDAQ:TECH) for US$15 million, adding the ExoDx Prostate urine test to its portfolio. The deal also includes a CLIA-certified clinical laboratory and related assets. The deal is expected to generate over US$20 million in revenue in 2026. <\/p>\n<\/div>\n

\n

2. KORU Medical Systems (NASDAQ:KRMD)<\/h3>\n

<\/span>Year-on-year gain:<\/strong> 50.13 percent
Market cap:<\/strong> US$269.6 million
Share price:<\/strong> US$5.82<\/p>\n

KORU Medical Systems develops and manufactures medical devices and supplies in the US and internationally, with a focus on mechanical infusion products. Its Freedom Syringe Infusion System first received FDA clearance in 1994.<\/p>\n

Based on this system, its primary products include the Freedom60 and FreedomEdge syringe infusion systems, Precision Flow Rate Tubing and High-Flo Subcutaneous Safety Needle Sets.<\/p>\n

KORU Medical Systems submitted a 510(k) premarket notification to the FDA on December 30, 2025, seeking clearance for its FreedomEdge system to deliver Phesgo \u2014 a HER2+ breast cancer targeted biologic \u2014 subcutaneously, targeting infusion centers to cut chair time and boost efficiency.<\/p>\n

The company stated this is part of its strategy to expand the indications of FreedomEdge to the wider oncology infusion center market.<\/p>\n<\/div>\n

\n

3. Vivani Medical (NASDAQ:VANI)<\/h3>\n

Year-on-year gain:<\/strong> 1.71 percent
Market cap:<\/strong> US$86.81 million
Share price:<\/strong> US$1.19<\/p>\n

Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, long-term subdermal drug implants using its proprietary NanoPortal technology to treat chronic conditions like obesity and type 2 diabetes.<\/p>\n

Headquartered in Alameda, California, Vivani focuses on GLP-1 implants that provide steady drug release over six months to improve adherence and tolerability compared to daily pills or weekly injections.<\/p>\n

<\/span>In August, Vivani Medical reported positive Phase 1 results from its LIBERATE-1 trial of the NPM-115 exenatide implant, confirming safety and steady drug release for obesity treatment without major side effects. <\/p>\n

The company plans to rapidly advance its NPM-139 semaglutide implant after it achieved preclinical results of sustained 20 percent weight loss. It is planning a Phase 1 clinical study in the first half of 2026. <\/p>\n<\/div>\n

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.<\/strong><\/p>\n<\/p>\n

This post appeared first on investingnews.com<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in…<\/p>\n","protected":false},"author":1,"featured_media":4913,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[40],"tags":[],"class_list":["post-4912","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investing"],"_links":{"self":[{"href":"https:\/\/profitalarm.com\/index.php\/wp-json\/wp\/v2\/posts\/4912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/profitalarm.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/profitalarm.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/profitalarm.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/profitalarm.com\/index.php\/wp-json\/wp\/v2\/comments?post=4912"}],"version-history":[{"count":0,"href":"https:\/\/profitalarm.com\/index.php\/wp-json\/wp\/v2\/posts\/4912\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/profitalarm.com\/index.php\/wp-json\/wp\/v2\/media\/4913"}],"wp:attachment":[{"href":"https:\/\/profitalarm.com\/index.php\/wp-json\/wp\/v2\/media?parent=4912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/profitalarm.com\/index.php\/wp-json\/wp\/v2\/categories?post=4912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/profitalarm.com\/index.php\/wp-json\/wp\/v2\/tags?post=4912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}